

# Lutz Naehrlich

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5815927/publications.pdf>

Version: 2024-02-01

51  
papers

4,225  
citations

257450

24  
h-index

175258

52  
g-index

54  
all docs

54  
docs citations

54  
times ranked

4814  
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapy of CF-Patients with Amitriptyline and Placebo - a Randomised, Double-Blind, Placebo-Controlled Phase IIb Multicenter, Cohort-Study. <i>Cellular Physiology and Biochemistry</i> , 2013, 31, 505-512.	1.6	1,925
2	The future of cystic fibrosis care: a global perspective. <i>Lancet Respiratory Medicine</i> , 2020, 8, 65-124.	10.7	573
3	Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial. <i>Lancet Respiratory Medicine</i> , 2017, 5, 557-567.	10.7	243
4	Concordant genotype of upper and lower airways <i>P aeruginosa</i> and <i>S aureus</i> isolates in cystic fibrosis. <i>Thorax</i> , 2009, 64, 535-540.	5.6	169
5	Impact of COVID-19 on people with cystic fibrosis. <i>Lancet Respiratory Medicine</i> , 2020, 8, e35-e36.	10.7	114
6	Preventive Inhalation of Hypertonic Saline in Infants with Cystic Fibrosis (PRESIS). A Randomized, Double-Blind, Controlled Study. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019, 199, 1238-1248.	5.6	96
7	Effects of Lumacaftor–Ivacaftor Therapy on Cystic Fibrosis Transmembrane Conductance Regulator Function in Phe508del Homozygous Patients with Cystic Fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 1433-1442.	5.6	95
8	Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two <i>F508del</i> Alleles. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2022, 205, 540-549.	5.6	78
9	Multicentre standardisation of chest MRI as radiation-free outcome measure of lung disease in young children with cystic fibrosis. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 518-527.	0.7	68
10	Serine Proteases Degrade Airway Mucins in Cystic Fibrosis. <i>Infection and Immunity</i> , 2011, 79, 3438-3444.	2.2	56
11	Repaglinide versus insulin for newly diagnosed diabetes in patients with cystic fibrosis: a multicentre, open-label, randomised trial. <i>Lancet Diabetes and Endocrinology</i> , 2018, 6, 114-121.	11.4	53
12	High Variability in Oral Glucose Tolerance among 1,128 Patients with Cystic Fibrosis: A Multicenter Screening Study. <i>PLoS ONE</i> , 2014, 9, e112578.	2.5	49
13	Cystic Fibrosis. <i>Deutsches Ärzteblatt International</i> , 2017, 114, 564-574.	0.9	49
14	Prevalence of meconium ileus marks the severity of mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) gene. <i>Genetics in Medicine</i> , 2016, 18, 333-340.	2.4	37
15	A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 68-77.	0.7	37
16	Nasal potential difference measurements in diagnosis of cystic fibrosis: An international survey. <i>Journal of Cystic Fibrosis</i> , 2014, 13, 24-28.	0.7	34
17	Hermansky-Pudlak syndrome type 2 manifests with fibrosing lung disease early in childhood. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 42.	2.7	33
18	Three-center feasibility of lung clearance index in infants and preschool children with cystic fibrosis and other lung diseases. <i>Journal of Cystic Fibrosis</i> , 2018, 17, 249-255.	0.7	33

#	ARTICLE	IF	CITATIONS
19	Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 733-746.	10.7	33
20	Elexacaftor-Tezacaftor-Ivacaftor Treatment Reduces Abdominal Symptoms in Cystic Fibrosis-Early results Obtained With the CF-Specific CFAbd-Score. <i>Frontiers in Pharmacology</i> , 0, 13, .	3.5	33
21	Risk factors for respiratory <i>Aspergillus fumigatus</i> in German Cystic Fibrosis patients and impact on lung function. <i>Scientific Reports</i> , 2020, 10, 18999.	3.3	30
22	Serum Proteome Profiling Identifies Novel and Powerful Markers of Cystic Fibrosis Liver Disease. <i>PLoS ONE</i> , 2013, 8, e58955.	2.5	30
23	Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: Results from a prospective longitudinal cohort study. <i>PLoS ONE</i> , 2017, 12, e0178784.	2.5	29
24	TIMP-1/-2 and transient elastography allow non invasive diagnosis of cystic fibrosis associated liver disease. <i>Digestive and Liver Disease</i> , 2012, 44, 780-787.	0.9	26
25	A pilot study of the characterization of hepatic tissue strain in children with cystic-fibrosis-associated liver disease (CFLD) by acoustic radiation force impulse imaging. <i>Pediatric Radiology</i> , 2013, 43, 552-557.	2.0	26
26	Individualized vitamin A supplementation for patients with cystic fibrosis. <i>Clinical Nutrition</i> , 2013, 32, 805-810.	5.0	25
27	Altered relaxation times in MRI indicate bronchopulmonary dysplasia. <i>Thorax</i> , 2020, 75, 184-187.	5.6	22
28	Diabetes in Cystic Fibrosis: Multicenter Screening Results Based on Current Guidelines. <i>PLoS ONE</i> , 2013, 8, e81545.	2.5	22
29	Intestinal current measurement versus nasal potential difference measurements for diagnosis of cystic fibrosis: a case-control study. <i>BMC Pulmonary Medicine</i> , 2014, 14, 156.	2.0	18
30	Multicentre feasibility of multiple-breath washout in preschool children with cystic fibrosis and other lung diseases. <i>ERJ Open Research</i> , 2020, 6, 00408-2020.	2.6	18
31	Iodine deficiency and subclinical hypothyroidism are common in cystic fibrosis patients. <i>Journal of Trace Elements in Medicine and Biology</i> , 2013, 27, 122-125.	3.0	14
32	Is there evidence for correct diagnosis in cystic fibrosis registries?. <i>Journal of Cystic Fibrosis</i> , 2014, 13, 275-280.	0.7	14
33	Identification of Neutrophil Activation Markers as Novel Surrogate Markers of CF Lung Disease. <i>PLoS ONE</i> , 2014, 9, e115847.	2.5	14
34	Misdiagnosis of cystic fibrosis - Experience from Germany. <i>Journal of Cystic Fibrosis</i> , 2013, 12, 68-73.	0.7	11
35	Immunoglobulin E monitoring and reduction of omalizumab therapy in children and adolescents. <i>Allergy and Asthma Proceedings</i> , 2012, 33, 77-81.	2.2	10
36	The Changing Face of Cystic Fibrosis and Its Implications for Screening. <i>International Journal of Neonatal Screening</i> , 2020, 6, 54.	3.2	10

#	ARTICLE	IF	CITATIONS
37	Defective BACH1/HO-1 regulatory circuits in cystic fibrosis bronchial epithelial cells. <i>Journal of Cystic Fibrosis</i> , 2021, 20, 140-148.	0.7	10
38	A Phase 3, open-label, 96-week trial to study the safety, tolerability, and efficacy of tezacaftor/ivacaftor in children ≥6 years of age homozygous for F508del or heterozygous for F508del and a residual function CFTR variant. <i>Journal of Cystic Fibrosis</i> , 2022, 21, 675-683.	0.7	10
39	Balloon Dilation of an Esophageal Stenosis in a Patient with Recessive Dystrophic Epidermolysis <i>à</i> fBullosa. <i>Pediatric Dermatology</i> , 2000, 17, 477-479.	0.9	9
40	Nasal potential difference: Best or average result for CFTR function as diagnostic criteria for cystic fibrosis?. <i>Journal of Cystic Fibrosis</i> , 2015, 14, 310-316.	0.7	9
41	Functional Characterization of a Novel CFTR Mutation P67S Identified in a Patient with Atypical Cystic Fibrosis. <i>Cellular Physiology and Biochemistry</i> , 2007, 19, 239-248.	1.6	8
42	Risk factors for cystic fibrosis arthropathy: Data from the German cystic fibrosis registry. <i>Journal of Cystic Fibrosis</i> , 2021, 20, e87-e92.	0.7	6
43	Sweat testing in CF. <i>Thorax</i> , 2007, 62, 462-462.	5.6	5
44	Infection prevention and control in patients with cystic fibrosis (CF): Results from a survey in 35 German CF treatment centers. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 384-387.	0.7	4
45	Langzeitbeatmung respirator-abh $\ddot{a}$ ngiger Kinder mit schweren Atemregulationst $\ddot{a}$ ndrungen bei Myelomeningozele und Chiari-II-Malformation. <i>Monatsschrift Fur Kinderheilkunde</i> , 2000, 148, 837-840.	0.1	2
46	Endoscopic Cystogastrostomy of a Pancreatic Retention Cyst in Cystic Fibrosis. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2005, 41, 477-478.	1.8	2
47	Neonatal Cystic Fibrosis Screening. <i>Deutsches A&amp;#x0308;rzteblatt International</i> , 2013, 110, 354-5.	0.9	2
48	Prader-Willi-Syndrom. <i>Monatsschrift Fur Kinderheilkunde</i> , 1997, 145, 515-518.	0.1	1
49	Cystic fibrosis transmembrane conductance regulator biomarkers in <i>â</i> real life $\text{â}$ <sup>TM</sup> : can we evaluate individual efficacy of cystic fibrosis transmembrane conductance regulator therapy?. <i>Therapeutic Advances in Respiratory Disease</i> , 2015, 9, 198-200.	2.6	1
50	Misdiagnosis of Cystic Fibrosis Based on Transient Pancreatic Insufficiency and Elevated Sweat Chloride. <i>Klinische Padiatrie</i> , 2015, 227, 96-97.	0.6	1
51	Have courage in using nasal potential difference for diagnostic decisions and clinical research. <i>Journal of Cystic Fibrosis</i> , 2020, 19, 507-508.	0.7	0